Table 2 Baseline characteristics of the patients in different risk groups
Characteristics | Freiburg cohort | Siena cohort | Leuven cohort | ||||||
|---|---|---|---|---|---|---|---|---|---|
High risk | Low risk | P value | High risk | Low risk | P valve | High risk | Low risk | P value | |
Age, years | 65.74 ± 10.06 | 69.06 ± 7.82 | 0.262 | 70.08 ± 11.34 | 67.28 ± 11.13 | 0.383 | 68.53 ± 7.80 | 67.97 ± 9.35 | 0.795 |
≥ 60 | 22 (71.0) | 27 (87.1) | 0.119 | 20 (80.0) | 22 (88.0) | 0.702 | 29 (90.6) | 27 (84.4) | 0.708 |
< 60 | 9 (29.0) | 4 (12.9) |  | 5 (20.0) | 3 (12.0) |  | 3 (9.4) | 5 (15.6) |  |
Gender | Â | Â | 1.000 | Â | Â | 0.480 | Â | Â | 0.120 |
Female | 5 (16.1) | 4 (12.9) | Â | 4 (16.0) | 6 (24.0) | Â | 4 (12.5) | 9 (28.1) | Â |
Male | 26 (83.9) | 27 (87.1) | Â | 21 (84.0) | 19 (76.0) | Â | 28 (87.5) | 23 (71.9) | Â |
GAP | Â | Â | 0.027 | Â | Â | 0.051 | Â | Â | 0.080 |
Stage I | 4 (12.9) | 13 (41.9) | Â | 5 (20.0) | 9 (36.0) | Â | 8 (25.0) | 17 (53.1) | Â |
Stage II | 18 (58.1) | 14 (45.2) | Â | 8 (32.0) | 12 (48.0) | Â | 19 (59.4) | 12 (37.5) | Â |
Stage III | 9 (29.0) | 4 (12.9) | Â | 12 (48.0) | 4 (16.0) | Â | 5 (15.6) | 3 (9.4) | Â |
Survival status |  |  |  < 0.001 |  |  | 0.001 |  |  | 0.002 |
Dead | 29 (93.5) | 16 (51.6) | Â | 21 (84.0) | 10 (40.0) | Â | 18 (56.3) | 6 (18.8) | Â |
Censored | 2 (6.5) | 15 (48.4) | Â | 4 (16.0) | 15 (60.0) | Â | 14 (43.7) | 26 (81.2) | Â |